Treating community-acquired bacterial respiratory tract infections: Update on etiology, diagnosis, and antimicrobial therapy

Journal of Family Practice

Volumn 54, Issue 4, 2005, Pages 357-364

  Brunton, I Stephen ^a  

^a AMERICAN ACADEMY OF FAMILY PHYSICIANS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; KETOLIDE; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN; TETRACYCLINE;

ACUTE BACTERIAL EXACERBATION OF CHRONIC BRONCHITIS; ACUTE BACTERIAL SINUSITIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; CHRONIC BRONCHITIS; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG SURVEILLANCE PROGRAM; HAEMOPHILUS INFLUENZAE; HUMAN; MEDICAL DECISION MAKING; MORAXELLA CATARRHALIS; PRESCRIPTION; PRIMARY MEDICAL CARE; RESPIRATORY TRACT INFECTION; REVIEW; SINUSITIS; STREPTOCOCCUS PNEUMONIAE; TIMED DRUG RELEASE;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; RESPIRATORY TRACT INFECTIONS;

EID: 16844379717     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Whitney CG, Farley MM, Hadler J, et al, for the Active Bacterial Core Surveillance Program of the Emerging Infections Program network. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 2000;343:1917-1924.
2. Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN; the Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother. 2003;52:229-246.
3. File TM, Jr. Overview of community-acquired respiratory tract infections. In: Nightingale CH, Ambrose PG, File TM, Jr., eds. Community-Acquired Respiratory Infections: Antimicrobial Management. New York, NY: Marcel Dekker, Inc; 2003:1-30.
4. Ben-David D, Rubinstein E. Appropriate use of antibiotics for respiratory infections: review of recent statements and position papers. Curr Opin Infect Dis. 2002;15:151-156.
5. Gonzales R, Malone DC, Maselli JH, Sande MA. Excessive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis. 2001;33:757-762.
6. Gwaltney JM, Jr. Acute community-acquired sinusitis. Clin Infect Dis. 1996;23:1209-1225.
7. Niederman MS, Mandell LA, Anzueto A, et al; American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730-1754.
8. Anon JB, Jacobs MR, Poole MD, et al; Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg. 2004;130:1-45.
9. Snow V, Mottur-Pilson C, Gonzales R, for the American College of Physicians-American Society of Internal Medicine. Principles of appropriate antibiotic use for treatment of acute bronchitis in adults. Ann Intern Med. 2001;134:518-520.
10. Mandell LA, Bartlett JG, Dowell SF, File TM, Jr., Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 2003;37:1405-1433.
11. Gonzales R, Bartlett JG, Besser RE, et al. Principles of appropriate antibiotic use for treatment of uncomplicated acute bronchitis: background. Ann Intern Med. 2001;134:521-529.
12. Bishai WR. Issues in the management of bacterial sinusitis. Otolaryngol Head Neck Surg. 2002;127:S3-S9.
13. Osguthorpe JD. Adult rhinosinusitis: diagnosis and management. Am Fam Physician. 2001;63:69-76.
14. Lindbaek M, Hjortdahl P, Johnsen UL. Use of symptoms, signs, and blood tests to diagnose acute sinus infections in primary care: comparison with computed tomography. Fam Med. 1996;28:183-188.
15. Williams JW Jr, Holleman DR Jr, Samsa GP, Simel DL. Randomized controlled trial of 3 vs 10 days of trimethoprim/sulfamethoxazole for acute maxillary sinusitis. JAMA. 1995;273:1015-1021.
16. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204.
17. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest. 2000;117:3805-3855.
18. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117:398S-401S.
19. Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA. 1997;278:1440-1445.
20. Lonks JR. What is the clinical impact of macrolide resistance? Curr Infect Dis Rep. 2004;6:7-12.
21. Sokol W. Epidemiology of sinusitis in the primary care setting: results from the 1999-2000 Respiratory Surveillance Program. Am J Med. 2001;111(suppl 9A):19S-24S.
22. Appelbaum PC. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin Infect Dis. 2002;34:1613-1620.
23. Doern GV, Brueggemann AB, Huynh H, Wingert E, Rhomberg P. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-1998. Emerg Infect Dis. 1999;5:757-765.
24. Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J Infect. 2004;48:56-65.
25. Pfaller MA, Jones RN. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections. Diagn Microbiol Infect Dis. 2002;44:77-84.
26. Hoban D, Waites K, Felmingham D. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study. Diagn Microbiol Infect Dis. 2003;45:251-259.
27. Dunbar LM. Current issues in the management of bacterial respiratory tract disease: the challenge of antibacterial resistance. Am J Med Sci. 2003;326:360-368.
28. Garau J. The hidden impact of antibacterial resistance in respiratory tract infection. Clinical failures: the tip of the iceberg? Respir Med. 2001;95(suppl A):S5-11.
29. File TM, Jr., Jacobs MR, Poole MD, Wynne B; 546, 547, 548, 549, 550, 551, 556, 557 and 592 Clinical Study Groups. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate. Int J Antimicrob Agents. 2002;20:235-247.
30. Amsden GW. Pneumococcal macrolide resistance: myth or reality? J Antimicrob Chemother. 1999;44:1-6.
31. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units. Implications for fluoroquinolone use. JAMA. 2003;289:885-888.
32. Brook I, Gooch WM 3rd, Jenkins SG, et al. Medical management of acute bacterial sinusitis. Recommendations of a clinical advisory committee on pediatric and adult sinusitis. Ann Otol Rhinol Laryngol Suppl. 2000;182:2-20.
33. Benninger MS, Sedory Holzer SE, Lau J. Diagnosis and treatment of uncomplicated acute bacterial rhinosinusitis: summary of the Agency for Health Care Policy and Research evidence-based report. Otolaryngol Head Neck Surg. 2000;123: 665-667.
34. Snow V, Mottur-Pilson C, Hickner JM. Principles of appropriate antibiotic use for acute sinusitis in adults. Ann Intern Med. 2001;134:495-497.
35. Hickner JM, Bartlett JG, Besser RE, et al. Principles of appropriate antibiotic use for acute rhinosinustis in adults. Background. Ann Intern Med. 2001;123:498-505.
36. Tankovic J, Bachoual R, Ouabdesselam S, Boudjadja A, Soussy CJ. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis. J Antimicrob Chemother. 1999;43 (suppl B):19-23.
37. Andrews JM, Weller TMA, Ashby JP, Walker RM, Wise R. The in vitro activity of ABT773, a new ketolide antimicrobial agent. J Antimicrob Chemother. 2000;46:1017-1022.
38. Cunha BA. Empiric therapy of community-acquired pneumonia: guidelines for the perplexed? Chest. 2004;125:1913-1919.
39. File TM Jr, Garau J, Blasi F, et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 2004;125:1888-1901.
40. Maglio D, Nicolau DP. Antimicrobial efficacy review. Infect Dis. 2004;7:33-36.
41. Sobol SE, Schloss MD, Tewfik TL. Sinus, acute, medical treatment. Available at: http://www.emedicine.com/ENT/topic337.htm. Accessed January 4, 2005.
42. Tse J, Cosep ML, Aminimanizani A, Gill MA. Community-acquired pneumonia. California Pharmacist Winter. 2002-2003:54-65.
43. Full US Prescribing Information for Ketek. Available at: http://www.aventis-US.com/PIs/ketek_TXT.html. Accessed January 4, 2005.
44. Full US Prescribing Information for Avelox. Available at: http://www.univgraph.com/bayer/inserts/Avolox.pdf. Accessed January 4, 2005.